SHIELD THERAPEUTICS PLC
A specialty pharmaceutical company focused on addressing iron deficiency in adults.
STX | IL
Overview
Corporate Details
- ISIN(s):
- GB00BYV81293
- LEI:
- 213800G74QWY15FC3W71
- Country:
- United Kingdom
- Address:
- NORTHERN DESIGN CENTRE STUDIO 6, 3RD FLOOR, NE8 3DF GATESHEAD
- Sector:
- Manufacturing
Description
Shield Therapeutics is a commercial-stage specialty pharmaceutical company focused on addressing iron deficiency. The company's mission is to improve the lives of patients suffering from this condition, with or without anemia. Its lead product is Accrufer® (ferric maltol), also marketed as Feraccru®, a novel, stable, non-salt-based oral therapy. This innovative pharmaceutical is broadly indicated for use in adults across multiple therapeutic categories, aiming to provide an effective and well-tolerated treatment for a significant unmet medical need.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Type / Size | Actions | |
|---|---|---|---|---|---|
| 2024-12-23 08:00 |
Results of RetailBook Offer
|
English | DOC • 20.0 KB | ||
| 2024-12-06 12:31 |
RetailBook Offer
|
English | DOC • 31.8 KB | ||
| 2024-12-06 12:30 |
Subscription by AOP Health to raise US$10 million
|
English | DOC • 190.9 KB | ||
| 2024-11-21 08:00 |
Business Update
|
English | DOC • 21.1 KB | ||
| 2024-10-29 08:00 |
Q3 Trading Update
|
English | DOC • 27.7 KB | ||
| 2024-09-25 08:00 |
Results from Phase 3 paediatric study
|
English | DOC • 23.6 KB | ||
| 2024-09-04 08:00 |
Interim results
|
English | DOC • 257.3 KB | ||
| 2024-08-27 08:00 |
ACCRUFeR® Approved by Health Canada
|
English | DOC • 19.9 KB | ||
| 2024-08-14 08:00 |
Notice of interim results
|
English | DOC • 16.6 KB | ||
| 2024-07-24 08:01 |
Unaudited Q2 2024 Trading Update
|
English | DOC • 21.7 KB | ||
| 2024-07-24 08:00 |
Directorate Change
|
English | DOC • 17.8 KB | ||
| 2024-07-03 08:00 |
$5.7m Milestone Monetization Agreement with AOP
|
English | DOC • 26.7 KB | ||
| 2024-06-20 17:25 |
Results of 2024 Annual General Meeting
|
English | DOC • 29.0 KB | ||
| 2024-05-28 08:00 |
New Drug Application for Accrufer® in South Korea
|
English | DOC • 20.1 KB | ||
| 2024-05-10 16:30 |
Audited results for the year ended 31 Dec 2023
|
English | DOC • 183.8 KB |
Automate Your Workflow. Get a real-time feed of all SHIELD THERAPEUTICS PLC filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for SHIELD THERAPEUTICS PLC
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for SHIELD THERAPEUTICS PLC via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
